The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Psoriasis affects your body’s immune system, causing it to produce too many skin cells. Those extra cells build up and create a flaky rash that may appear red, purple, ashen gray, or brown ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Plaque psoriasis-often mistaken for dry skin or eczema-isn't always easy to manage and usually causes discomfort. Recently, the actress and TV personality opened up to First For Women about her ...

Plaque psoriasis is the most common type of psoriasis. Plaques are pink/red, raised, thick, inflamed skin patches covered by silvery-white scales. They typically have well-defined edges and may itch.

Plaque psoriasis, a chronic autoimmune disorder that causes thick, scaly, itchy patches—the eponymous plaques—to form on the skin, affects more than 7.5 million adults in the United States.

On Oct. 1, actress and media personality La La Anthony shared her ongoing struggle with plaque psoriasis on Instagram ... unique challenges for Black women who often wear protective styles ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...

An analysis of a large general practice database showed that patients with severe plaque psoriasis for 3-6 years had a 50% higher relative risk of premature mortality. On average, men and women ...

The trial investigators wanted to see if the drug was an effective psoriasis treatment because of its immune-dampening and itch-reducing effects. A total of 432 patients (56.3% women) aged 12 and ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ...